Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen

Nature Protocols

Volumn 4, Issue 3, 2009, Pages 372-384

  Smith, Kenneth ^a   Garman, Lori ^a   Wrammert, Jens ^b   Zheng, Nai Ying ^c   Capra, J Donald ^a   Ahmed, Rafi ^b   Wilson, Patrick C ^c,d  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Section of Rheumatology   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCING CELL; ANTIBODY SPECIFICITY; ARTICLE; BIOSYNTHESIS; CELL LINE; GENETICS; HUMAN; IMMUNOLOGY; VACCINATION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-PRODUCING CELLS; ANTIGENS; CELL LINE; HUMANS; VACCINATION;

EID: 63849240274     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2009.3     Document Type: Article

References (21)

1. Wrammert, J. et al. Rapid cloning of high affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671 (2008).
2. Lanzavecchia, A., Corti, D. & Sallusto, F. Human monoclonal antibodies by immortalization of memory B cells. Curr. Opin. Biotechnol. 18, 523-528 (2007).
3. Steinitz, M., Klein, G., Koskimies, S. & Makel, O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 269, 420-422 (1977).
4. Kozbor, D., Lagarde, A.E. & Roder, J.C. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc. Natl Acad. Sci. USA 79, 6651-6655 (1982).
5. Jones, P.T., Dear, P.H., Foote, J., Neuberger, M.S. & Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522-525 (1986).
6. McCafferty, J., Griffiths, A.D., Winter, G. & Chiswell, D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990).
7. Wardemann, H. etal. Predominantautoantibody production byearly human B cell precursors. Science 301, 1374-1377 (2003).
8. Tiller, T. etal. Efficient generation ofmonoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112-124 (2008).
9. Mohapatra, S. & San Juan, H. Designer monoclonalantibodies as drugs: the state of the art. Clin. Immunol. 4, 305-307 (2008).
10. Yu, X. et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455, 532-536 (2008).
11. Koelsch, K. et al. Mature B cells class switched to IgD are autoreactive in healthy individuals. J. Clin. Invest. 117, 1558-1565 (2007).
12. Duty, J.A. et al. Functionalanergyin a subpopulation ofnai've B cells from healthy humans that express autoreactive immunoglobulin receptors. J. Exp. Med. (in press).
13. Poulsen, T.R., Meijer, P.J., Jensen, A., Nielsen, L.S. & Andersen, P.S. Kinetic, affinity, and diversity limits of human polyclonal antibody responses against tetanus toxoid. J. Immunol. 179, 3841-3850 (2007).
14. Keller, M.A. & Steihm, E.R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602-614 (2000).
15. Ahmed, R., Oldstone, M.B. & Palese, P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat. Immunol. 8, 1188-1193 (2007).
16. Karlsson Hedestam, G.B. et al. The challenges ofeliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 6, 143-155 (2008).
17. Patti, J.M. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22, S39-S43 (2004).
18. Crotty, S., Aubert, R.D., Glidewell, J. & Ahmed, R. Tracking human antigen- specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286, 111-122 (2004).
19. Graham, F.L. et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72 (1977).
20. Boussif, O. et al. A versatile vectorforgene and oligonucleotide transferinto cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92, 7297-7301 (1995).
21. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases 10th edn. (eds. Atkinson, W., Hamborsky, J., McIntyre, L. & Wolfe, S.) (Centers for Disease Control and Prevention, Washington, DC, 2008).